Eric T. Gangl

AstraZeneca (South Korea) — South Korea

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.1kcitations159works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(35), Synthesis and Catalytic Reactions(26), Mast cells and histamine(24), Cytokine Signaling Pathways and Interactions(24), Advanced Breast Cancer Therapies(23)

Publications159 total

Abstract PS1-10-28: Phase 1/2a trial of new generation PARP1-selective inhibitor saruparib + next generation selective ER degrader (SERD) camizestrant in patients (pts) with advanced/relapsed ER+/HER2-negative or low (HER2−) breast cancer (PETRA Module 6)
Clinical Cancer Research·2026
Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Clinical and Translational Science·2026· 1 citedOpen Access
Supplementary Figure 1 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025Open Access
Supplementary Figure 4 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025Open Access
Supplementary Figure 3 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025Open Access
Supplementary Table 1 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025Open Access
Supplementary Figure 5 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025Open Access
Supplementary Figure 2 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025Open Access
The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile
Drug Metabolism and Disposition·2025· 4 citedOpen Access
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study
British Journal of Cancer·2025· 7 citedOpen Access
Abstract 1158: Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer
Cancer Research·2025
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
Journal of Medicinal Chemistry·2024· 5 cited
Design and Synthesis of Acyclic Boronic Acid Arginase Inhibitors
Journal of Medicinal Chemistry·2024· 5 cited
Supplementary Figure 3 from Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
2024Open Access
Supplementary Figure 4 from Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
2024Open Access
Supplementary Figure 5 from Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
2024Open Access
Supplementary Figure 5 from Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
2024Open Access
Supplementary Figure 4 from Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
2024Open Access
Supplementary Figure 1 from Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
2024Open Access
Data from Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
2024Open Access
page 1 of 8Next →

Frequent Co-authors

James S. Scott(9), Petar Pop-Damkov(9), Teresa Klinowska(8), Alwin G. Schuller(7), Mandy Lawson(6), Christopher J. Morrow(6), Radosław Polański(6), Francis D. Gibbons(5), Stephen E. Fawell(5), Paul Vouros(5), Tom Moss(5), Rodrigo J. Carbajo(5), William McCoull(5), Shenghua Wen(5), Ammar Adam(4), Wenzhan Yang(4), Xiaolan Zheng(4), J. Paul Secrist(4), Paul R. J. Davey(4), David I. Fisher(4)